scholarly journals AB0546 5 YEARS FOLLOW-UP OF PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TREAT-TO-TARGET STRATEGY. PRELIMINARY RESULTS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1306.1-1306
Author(s):  
P. Tremaskina ◽  
E. Loginova ◽  
T. Korotaeva ◽  
S. Glukhova ◽  
A. Lila
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Standard Care ◽  
Early Stage ◽  
Treat To Target ◽  
Moderate Activity ◽  
Long Term Outcomes ◽  
Mean Values

Background:The concept of treat to target (T2T) in psoriatic arthritis (PsA) has been established recently and already shown its benefits [1]. But the long-term outcomes of the T2T have not been studied yet.Objectives:To study 5 years (yrs) follow-up of PsA patients (pts) treated according to T2T strategy at the early stage.Methods:35 (M/F–17/18) PsA pts fulfilling CASPAR criteria, who were treated according to T2T strategy at the early stage (PsA duration≤2 yrs) within 24 months (mos) were analyzed. At the time of evaluation mean age is 42.7±11.2 yrs, median (Me) PsA duration 72 [60;95] mos, psoriasis duration 120 [88;180] mos. All pts underwent standard clinical examinations of PsA before started T2T therapy and at follow-up. Within 24 mos of T2T strategy all pts were taking Methotrexate (MTX) monotherapy in increasing dose up to 25 mg/wk and 18 out of 35 (51%) pts received MTX in combination with iTNF. When T2T study was stopped all pts were treated according to standard care with NSAIDs, bDMARDs, MTX, tsDMARDs based on PsA activity and physician decision. The number of pts achieved minimal disease activity (MDA, 5 of 7) and remission by DAPSA (≤4)/low disease activity (LDA)≤14) at the 24 mos of T2T strategy and at 5 yrs follow-up were calculated. The results are presented in the form of mean values, median, upper and lower quartiles.Results:Me duration of follow-up is 68 [53.5;81.5] mos. At 24 mos Me DAPSA 3.48 [0.45;21.76], remission by DAPSA (REM-DAPSA) were seen in 20 out of 35 (57%) pts, LDA-DAPSA in 4 (12%) pts, moderate activity (MoA) by DAPSA in 6 (17%) pts and high disease activity by DAPSA (HDA-DAPSA) in 5 (14%) pts. MDA was noted in 21 out of 35 (60%) pts. At 5 yrs Me DAPSA 7.4 [2.22;13.87], REM-DAPSA was noted in 12 (34%) pts, LDA-DAPSA in 14 (40%), MoA-DAPSA in 5 (14%), HDA-DAPSA in 4 (12%) pts. MDA was observed in 17 of 35 pts (49%). Among 20 pts who had REM-DAPSA at 24 mos only 6 pts (30%) remained in remission at 5 yrs follow-up and 12 out of 21 pts (57.14%) remained in MDA status.Conclusion:In early PsA pts remission and MDA are achievable goal of T2T strategy. But most pts lost remission/MDA after this strategy was changed to a standard care, despite being in remission/MDA status before change of therapy. Further investigations of the long-term outcomes of T2T strategy in PsA, including radiographic outcomes are needed.References:[1]Coates LC, Moverley AR, McParland L, et al. Lancet 2015; 386: 2489–98.Disclosure of Interests:None declared.

scholarly journals P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S353-S354
Author(s):  
L Derikx ◽  
H Dolby ◽  
N Plevris ◽  
L Lucaciu ◽  
C Rees ◽  
...  
Keyword(s):  
Adverse Event ◽  
Disease Activity ◽  
Injection Site ◽  
Cost Savings ◽  
Common Adverse Event ◽  
Prescription Database ◽  
Long Term Outcomes ◽  
Faecal Calprotectin

Abstract Background Multiple adalimumab (ADA) biosimilars, including SB5 (Imraldi) and ABP 501 (Amgevita), are now approved for use in IBD. Data about biosimilar ADA in IBD remain scarce. We therefore aimed to investigate long-term outcomes of the biosimilar SB5 in IBD patients following a switch from the ADA originator (Humira) or after start of SB5 as their first ADA-therapy. Methods We performed a retrospective cohort study in a tertiary IBD referral centre. All IBD patients treated with Humira underwent an elective switch to SB5 regardless of IBD phenotype, disease activity and ADA dosing. All patients were reviewed regularly in the virtual biologics clinic with protocol driven collection of clinical disease activity, blood tests, TDM and faecal calprotectin. We identified all patients on SB5 in a biologic prescription database that prospectively registered all ADA by brand name and start and stop dates. Results 441 patients were treated with SB5, including 234 who switched from Humira to SB5 (CD=209, 89.3%; median IBD duration 10 years, IQR 6-16) and 207 who started on SB5 as their first ADA-therapy (CD=162, 78.3%; median IBD duration 6 years, IQR 1-16.8). 107/234 (45.7%) patients who switched to SB5 used infliximab before ADA. These patients were treated for a median of 32 months (IQR 17-57) with Humira prior to switching. At Humira – SB5 switch, 60.1% (140/234) received 40mg ADA every other week and 39.1% (91/234) once weekly. The median duration of follow up was 13 months (IQR 8-14). At week 26 and week 52, 194/231 (84.1%) and 148/215 (70.3%) patients remained on SB5, respectively (Figure 1). 81/234 patients (35.0%) discontinued SB5, mostly due to adverse events (n=40/81) or secondary loss of response (n=35/81). Pain at the injection site was the most frequently reported adverse event (n=31); all these patients switched to Amgevita. 30/31 patients with a double biosimilar continued Amgevita until the end of follow up (median 30 months), resulting in 172/215 (81.3%) patients that remained on ADA at week 52 (Figure 1). Proportions of patients in biochemical remission and clinical remission were similar at baseline, week 26 and week 52 following switch (Figure 2). Median ADA trough levels were similar before (10.2 ug/ml, IQR 7.4-13.5) and after switch 10.3 (IQR 7.4-13.1). 17/234 (7.3%) patients developed antibodies during SB5 treatment. Conclusion Switching from Humira to SB5 appeared effective and safe in this study with over 12 months of follow up. The most common adverse event was injection site pain; these patients were successfully moved on to Amgevita providing the first data about a double biosimilar switch. Over the 24 months of this biosimilar ADA program substantial cost savings were effected.

Ten‐year follow‐up study of long‐term outcomes after conservative surgery for early‐stage ovarian cancer

2020 ◽  
Vol 150 (2) ◽  
pp. 169-176 ◽  
Author(s):  
Giorgio Bogani ◽  
Antonino Ditto ◽  
Ciro Pinelli ◽  
Salvatore Lopez ◽  
Valentina Chiappa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Early Stage ◽  
Conservative Surgery ◽  
Long Term Outcomes ◽  
Follow Up Study ◽  
Early Stage Ovarian Cancer

scholarly journals The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategy

2020 ◽  
Vol 14 (3) ◽  
pp. 91-96
Author(s):  
P. O. Tremaskina ◽  
E. Yu. Loginova ◽  
T. V. Korotaeva ◽  
A. V. Sukhinina
Keyword(s):  
Psoriatic Arthritis ◽  
Early Stage ◽  
Treat To Target ◽  
Open Label ◽  
Basic Principles ◽  
Follow Up Study ◽  
Structural Progression ◽  
First Results ◽  
Observational Cohort

The paper characterizes the basic principles of a treat-to-target (T2T) strategy for spondyloarthritis, including psoriatic arthritis (PsA). The data from observational cohort studies suggest that inadequate therapy for PsA increases the risk of structural progression. The results, obtained in the international randomized controlled Tight Control of Psoriatic Arthritis (TICOPA) trial and the Russian open-label observational REMARCA study, have justified the necessity of using the T2T strategy for early-stage PsA. The authors have analyzed their own results of a 6-year follow-up study of a patient with early PsA, in whom the T2T strategy was used.

Temporal associations between prognostic indicators and overall survival after breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18144-e18144
Author(s):  
Jennifer Kay Plichta ◽  
Samantha Marie Thomas ◽  
Oluwadamilola Motunrayo Fayanju ◽  
Laura Horst Rosenberger ◽  
Tristen Sinae Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Prognostic Indicators ◽  
Multiple Time ◽  
Long Term Outcomes ◽  
Multiple Time Points

e18144 Background: Breast oncologists have little guidance on predicting long term outcomes after interval survival. We aim to evaluate the association of overall survival (OS) with select factors at multiple time points. Methods: Women ages 18-80 with non-metastatic invasive breast cancer were identified from the NCDB (2004─2014). Using multivariate survival analysis, we estimated the association of OS with tumor and treatment factors for those with follow up surviving at least 2, 5, and 10y post-diagnosis. Results: 685598 women (median age 59) were identified; 573757 were alive with follow up at 2y, 254303 at 5y, and 18640 at 10y. The majority had early stage, hormone receptor (HR) +, invasive ductal carcinoma. 57% underwent lumpectomy; 49% received chemotherapy; 89% of lumpectomies received radiation (RT); and 83% of HR+ tumors received endocrine therapy (ET). Of those alive at 2y, improved OS was associated with ER+, PR+, chemotherapy, RT, and ET. Reduced OS was associated with higher cT/cN stage, grade, and mastectomy. Of those alive at 5y, improved OS was associated with chemotherapy, RT, and ET. Reduced OS was associated with higher cT/cN stage, grade, and mastectomy. Of those alive at 10y, reduced OS was associated with higher cT stage and grade. Conclusions: Tumor and treatment factors are associated with OS, but the association of some factors may change for women surviving at least 5y or 10y. These findings may contribute to more tailored prognostication for patients based on interval survival. [Table: see text]

Periprocedural risk and long-term outcome of intracranial angioplasty based on a single-centre experience

VASA ◽  
2013 ◽  
Vol 42 (4) ◽  
pp. 264-274
Author(s):  
Dagmar Krajíčková ◽  
Antonín Krajina ◽  
Miroslav Lojík ◽  
Martina Mulačová ◽  
Martin Vališ
Keyword(s):  
Death Rate ◽  
Long Term Outcomes ◽  
Single Centre ◽  
Intracranial Atherosclerotic Stenosis ◽  
Atherosclerotic Stenosis ◽  
Angioplasty And Stenting ◽  
Aggressive Medical Management ◽  
Stroke Death

Background: Intracranial atherosclerotic stenosis is a major cause of stroke and yet there are currently no proven effective treatments for it. The SAMMPRIS trial, comparing aggressive medical management alone with aggressive medical management combined with intracranial angioplasty and stenting, was prematurely halted when an unexpectedly high rate of periprocedural events was found in the endovascular arm. The goal of our study is to report the immediate and long-term outcomes of patients with ≥ 70 % symptomatic intracranial atherosclerotic stenosis treated with balloon angioplasty and stent placement in a single centre. Patients and methods: This is a retrospective review of 37 consecutive patients with 42 procedures of ballon angioplasty and stenting for intracranial atherosclerotic stenosis (≥ 70 % stenosis) treated between 1999 and 2012. Technical success (residual stenosis ≤ 50 %), periprocedural success (no vascular complications within 72 hours), and long-term outcomes are reported. Results: Technical and periprocedural success was achieved in 90.5 % of patients. The within 72 hours periprocedural stroke/death rate was 7.1 % (4.8 % intracranial haemorrhage), and the 30-day stroke/death rate was 9.5 %. Thirty patients (81 %) had clinical follow-up at ≥ 6 months. During follow-up, 5 patients developed 6 ischemic events; 5 of them (17 %) were ipsilateral. The restenosis rate was 27 %, and the retreatment rate was 12 %. Conclusions: Our outcomes of the balloon angioplasty/stent placement for intracranial atherosclerotic stenosis are better than those in the SAMMPRIS study and compare favourably with those in large registries and observational studies.

Sign in / Sign up

Export Citation Format

Share Document